Stay updated with breaking news from Ryan Demasi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.
Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.
Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.